“The loss of $140 billion in revenues will take a large bite out of a global business that raked in sales of $643 billion last year, based on figures compiled by IMS Health. As a result, many investors are concerned drug companies do not have enough new compounds moving through development to keep sales and profits growing at historic levels.” – Reuters
“If the leading pharma companies are to maintain their 3.1% growth rate experienced in 2008–09 rather than the 0.9% growth rate currently forecast out to 2014, companies need to find an additional $64 billion in sales in 2014.” – Datamonitor
“Pharma will derive a majority of sales from external products by 2014 – as internally-developed drugs are set to decline by $10 billion in 2014 compared to 2009, Pharma is expected to rejuvenate its pipeline through externally sourced drugs, particularly via mergers and acquisitions (M&As) and co-development deals, given that externally derived R&D provides greater cost efficiencies.“ – Datamonitor
“Injectable drugs set to drive market growth – as oral formulations are intrinsically associated with small molecule drugs, these are set to lose $18 billion by 2014 due to strong generic competition. Conversely, the market for injectable drugs will continue to experience rapid expansion driven by the growth of biologics which are typically delivered via this mechanism.” – Datamonitor